ArticleJournal of gastroenterology2023
The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer.
Article in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Learning from an Emerging Infection: How the COVID-19 Pandemic Reshaped Gastric Cancer Care.Life (Basel, Switzerland) · 2026Review
- Diagnostic Delay and Mortality Risk in Gastric Cancer During the COVID-19 Pandemic: A Retrospective Tertiary-Center Study.Diagnostics (Basel, Switzerland) · 2025Article
- The Impact of Chemoradiotherapy on Nutritional Status and Quality of Life in Esophageal Cancer Patients during the COVID-19 Pandemic: A Retrospective Study in Taiwan.Journal of chest surgery · 2025Article
- The global, regional, and national burden of early, middle, and late-onset esophageal cancer and trends from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021.Journal of thoracic disease · 2025Article
- Association Between Pre-Diagnostic Delay and Survival Among Patients With Esophageal and Gastric Cancer Treated With Curative Intent During the COVID19 Pandemic.Cancer medicine · 2025Article
- Analysis of surgical volume and short-term outcomes for upper gastrointestinal cancer post-COVID-19: Evidence from a nationwide Japanese database.Annals of gastroenterological surgery · 2025Article
- Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021.Biomarker research · 2025Article
- IMPACT OF COVID-19 PANDEMIC ON THE SURGICAL TREATMENT OF GASTRIC CANCER: A 3-YEAR ANALYSIS.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- Palliative use of self-expanding metal stents in initially anticancer treatment-intolerant patients with esophageal cancer.BMC gastroenterology · 2024Article
- Digestive and breast cancer patients managed during the first wave of COVID-19 pandemic: Short and middle term outcomes.World journal of methodology · 2024Article
- Editorial: Comparisons of COVID-19-related disturbance in diagnosis of esophagogastric cancer between the Netherlands and Japan.Journal of gastroenterology · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundThe COVID-19 pandemic has affected the entire global healthcare system, including oncological care. This study investigated the effects of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer in the Netherlands.
methodsPatients diagnosed in 2020 were divided into 5 periods, based on the severity of the COVID-19 pandemic in the Netherlands, and compared to patients diagnosed in the same period in the years 2017-2019. Patient characteristics and treatments were evaluated for esophageal cancer (EC) and gastric cancer (GC) separately.
resultsThe number of esophagogastric cancer diagnoses decreased prominently during the first 2 months of the COVID-19 pandemic. During this period, a significantly higher percentage of GC patients was diagnosed with incurable disease (52.5% in 2017-2019 and 67.7% in 2020, p = 0.011). We observed a significant reduction in the percentage of patients with potentially curable EC treated with resection and neoadjuvant chemoradiotherapy (from 35.0% in 2017-2019 to 27.3% in 2020, p < 0.001). Also, patients diagnosed with incurable GC were treated less frequently with a resection (from 4.6% in 2017-2019 to 1.5% in 2020, p = 0.009) in the second half of 2020.
conclusionsCompared to previous years, the number of esophagogastric cancer diagnoses decreased in the first 2 months of the COVID-19 pandemic, while an increased percentage of patients was diagnosed with incurable disease. Both in the curative and palliative setting, patients were less likely to be treated with a surgical resection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.